True North Therapeutics is a clinical-stage biotechnology company based in South San Francisco developing products that selectively inhibit the Complement system to treat certain rare diseases. Its lead product candidate, TNT009, is designed to selectively inhibit a target in the Classical Complement pathway. The company intends to use proceeds from its recent financing to accelerate further development of TNT009 for Cold Agglutinin Disease (CAD) and other rare Complement-mediated diseases. CAD is a rare autoimmune disease involving destruction of red blood cells that can cause anemia, fatigue and potentially fatal thromboses; there are currently no approved pharmaceutical products for CAD in the U.S. or Europe. TNT009 received Orphan Drug designation from the U.S. FDA for autoimmune hemolytic anemia, including CAD, adding to a designation from the European Medicines Agency received in February 2016. The company is led by CEO Nancy Stagliano and completed a $45M Series D equity financing to fund its development plans. True North Therapeutics is a clinical-stage biotechnology company developing antibody therapies that selectively inhibit the Complement system to treat rare diseases. Its lead program, TNT009, is a first-in-class monoclonal antibody that targets C1s to selectively block the Classical Complement pathway. The company is positioning TNT009 for Cold Agglutinin Disease (CAD) and other complement-mediated indications across hematology, transplantation, and dermatology. True North initiated a Phase 1a clinical study with TNT009 earlier in 2015 and plans to begin a Phase 1b clinical study later this month. Proceeds from the recent financing will be used to advance TNT009 through potential registration-enabling studies for CAD and to progress additional complement inhibitors in its pipeline. True North is based in South San Francisco, California. True North Therapeutics is a biotechnology company developing a pipeline of novel therapies that selectively target the Complement pathway to address rare and antibody-driven diseases. Its lead candidate, TNT009, is a monoclonal antibody that inhibits C1s to selectively block the Classical Complement pathway while preserving the Alternative and Lectin pathways. The company plans a broad clinical program for TNT009, initiating a Phase 1a study in Q2 2015 and a Phase 1b program later in the year in indications including antibody-mediated rejection in kidney transplant and Cold Agglutinin Disease. Proceeds from a completed $35 million Series B equity financing will fund completion of clinical studies for TNT009 and advancement of a second preclinical drug candidate into clinical development. True North positions itself as the first company to selectively target Classical Complement pathway blockade across hematologic, kidney transplant, and skin therapeutic areas. The company is located in South San Francisco, California. True North Therapeutics is developing TNT009, a first-in-class monoclonal antibody that selectively inhibits C1s in the Classical Complement pathway. Preclinical studies showed ex vivo efficacy for TNT009. The company is focused on Complement-mediated rare diseases across hematologic, renal (including kidney transplant), neurological and dermatology areas. True North plans to advance TNT009 into clinical development with the initiation of first human trials planned for early 2015. The Series A financing will fund completion of Phase 1a and Phase 1b studies, including evaluation of patients with autoantibody-driven rare diseases mediated by the Complement system. True North was spun out from iPierian and is based in South San Francisco, California.

Total raised

$142M

Funding rounds

4

Latest round

Series D

Latest activity

Oct 2016